The authors used a high‐fat diet‐induced NAFLD mouse model to determine the impact of gut microbiota alterations on NAFLD, and found that inhibition of intestinal Farnesoid X receptor signalling was identified as a potential treatment for NAFLD.20 Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.